Cannabis Addiction and the Brain: a Review

Journal of Neuroimmune Pharmacology

Volumn 13, Issue 4, 2018, Pages 438-452

  Zehra, Amna ^a   Burns, Jamie ^a   Liu, Christopher Kure ^a   Manza, Peter ^a   Wiers, Corinde E ^a   Volkow, Nora D ^a,b   Wang, Gene Jack ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Dopamine; Marijuana; Substance use disorders; THC

Indexed keywords

CANNABIDIOL; CORTICOTROPIN RELEASING FACTOR; DELTA9 TETRAHYDRACANNABINOL; ENDOCANNABINOID; UNCLASSIFIED DRUG; CANNABINOID 1 RECEPTOR; CANNABIS;

ABSTINENCE; AMYGDALA; ANTICIPATION; ANXIETY ASSESSMENT; BASAL GANGLION; BEHAVIOR; BRAIN FUNCTION; CANNABIS ADDICTION; CANNABIS USE DISORDER; COGNITION; DORSAL STRIATUM; DRUG DEPENDENCE; DRUG SEEKING BEHAVIOR; DYSPHORIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INTELLIGENCE QUOTIENT; INTOXICATION; IRRITABILITY; MALAISE; MEMORY; MESOLIMBIC DOPAMINERGIC SYSTEM; NEUROBIOLOGY; NEUROIMAGING; NEUROPHYSIOLOGY; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; VERBAL LEARNING; WITHDRAWAL SYNDROME; ADDICTION; ANIMAL; BRAIN; CANNABIS SMOKING; DIAGNOSTIC IMAGING; DRUG EFFECT; METABOLISM; NERVE CELL NETWORK; NUCLEAR MAGNETIC RESONANCE IMAGING; PSYCHOLOGY; REINFORCEMENT;

ANIMALS; BEHAVIOR, ADDICTIVE; BRAIN; CANNABIS; HUMANS; MAGNETIC RESONANCE IMAGING; MARIJUANA ABUSE; MARIJUANA SMOKING; NERVE NET; RECEPTOR, CANNABINOID, CB1; REINFORCEMENT (PSYCHOLOGY);

EID: 85044231259     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-018-9782-9     Document Type: Review

References (116)

1. Albrecht DS, Skosnik PD, Vollmer JM, Brumbaugh MS, Perry KM, Mock BH, Zheng QH, Federici LA, Patton EA, Herring CM, Yoder KK (2013) Striatal D2/D3 receptor availability is inversely correlated with cannabis consumption in chronic marijuana users. Drug Alcohol Depend 128:52–57. 10.1016/j.drugalcdep.2012.07.016
2. Allsop D, Lintzeris N, Copeland J, Dunlop A, McGregor I (2015) Cannabinoid replacement therapy (CRT): nabiximols (Sativex) as a novel treatment for cannabis withdrawal. Clin Pharmacol Ther 97:571–574. 10.1002/cpt.109
3. Asevedo E, Mendes AC, Berk M, Brietzke E (2014) Systematic review of N-acetylcysteine in the treatment of addictions. Rev Bras Psiquiatr 36:168–175
4. Ashok AH, Mizuno Y, Volkow ND, Howes OD (2017) Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. JAMA Psychiat 74:511–519. 10.1001/jamapsychiatry.2017.0135
5. Balter RE, Cooper ZD, Haney M (2014) Novel pharmacologic approaches to treating cannabis use disorder. Curr Addict Rep 1:137–143. 10.1007/s40429-014-0011-1
6. Barkus E, Morrison PD, Vuletic D, Dickson JC, Ell PJ, Pilowsky LS, Brenneisen R, Holt DW, Powell J, Kapur S, Murray RM (2011) Does intravenous Delta9-tetrahydrocannabinol increase dopamine release? A SPET study. J Psychopharmacol 25:1462–1468. 10.1177/0269881110382465
7. Bayrakçi A, Sert E, Zorlu N et al (2015) Facial emotion recognition deficits in abstinent cannabis dependent patients. Compr Psychiatry 58:160–164. 10.1016/j.comppsych.2014.11.008
8. Becker MP, Collins PF, Luciana M (2014) Neurocognition in college-aged daily marijuana users. J Clin Exp Neuropsychol 36:379–398. 10.1080/13803395.2014.893996
9. Bhattacharyya S, Atakan Z, Martin-Santos R, A. Crippa J, K. McGuire P (2012) Neural mechanisms for the cannabinoid modulation of cognition and affect in man: a critical review of neuroimaging studies. Curr Pharm Des 18:5045–5054. 10.2174/138161212802884636
10. Bloomfield MAP, Morgan CJA, Kapur S, Curran HV, Howes OD (2014) The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study. Psychopharmacology 231:2251–2259. 10.1007/s00213-014-3523-4
11. Bloomfield MAP, Ashok AH, Volkow ND, Howes OD (2016) The effects of Δ9-tetrahydrocannabinol on the dopamine system. Nature 539:369–377. 10.1038/nature20153
12. Bossong MG, Mehta MA, Van Berckel BNM et al (2015) Further human evidence for striatal dopamine release induced by administration of δ9-tetrahydrocannabinol (THC): selectivity to limbic striatum. Psychopharmacology 232:2723–2729. 10.1007/s00213-015-3915-0
13. Brezing CA, Levin FR (2018) The current state of pharmacological treatments for cannabis use disorder and withdrawal. Neuropsychopharmacology 43:173–194. 10.1038/npp.2017.212
14. Broyd SJ, van Hell HH, Beale C, Yücel M, Solowij N (2016) Acute and chronic effects of cannabinoids on human cognition-a systematic review. Biol Psychiatry 79:557–567. 10.1016/j.biopsych.2015.12.002
15. Budney AJ, Vandrey RG, Hughes JR, Thostenson JD, Bursac Z (2008) Comparison of Cannabis and tobacco withdrawal: severity and contribution to relapse. J Subst Abus Treat 35:362–368. 10.1016/j.jsat.2008.01.002
16. Caballero A, Tseng KY (2012) Association of cannabis use during adolescence, prefrontal CB1 receptor signaling, and schizophrenia. Front Pharmacol 3:101. 10.3389/fphar.2012.00101
17. Caprioli D, Justinova Z, Venniro M, Shaham Y (2017) Effect of novel allosteric modulators of metabotropic glutamate receptors on drug self-administration and relapse: a review of preclinical studies and their clinical implications. Biol Psychiatry. 10.1016/j.biopsych.2017.08.018
18. Carliner H, Brown QL, Sarvet AL, Hasin DS (2017) Cannabis use, attitudes, and legal status in the U.S.: a review. Prev Med (Baltim). 10.1016/j.ypmed.2017.07.008
19. Colizzi M, McGuire P, Pertwee RG, Bhattacharyya S (2016) Effect of cannabis on glutamate signalling in the brain: a systematic review of human and animal evidence. Neurosci Biobehav Rev 64:359–381. 10.1016/j.neubiorev.2016.03.010
20. Crippa JAS, Derenusson GN, Chagas MHN, Atakan Z, Martín-Santos R, Zuardi AW, Hallak JEC (2012) Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature. Harm Reduct J 9:7. 10.1186/1477-7517-9-7
21. Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJA, Parsons LH (2016) Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci 17:293–306. 10.1038/nrn.2016.28
22. Cutando L, Busquets-Garcia A, Puighermanal E, Gomis-González M, Delgado-García JM, Gruart A, Maldonado R, Ozaita A (2013) Microglial activation underlies cerebellar deficits produced by repeated cannabis exposure. J Clin Invest 123:2816–2831. 10.1172/JCI67569
23. Cuttler C, Spradlin A, Nusbaum AT, Whitney P, Hinson JM, McLaughlin RJ (2017) Blunted stress reactivity in chronic cannabis users. Psychopharmacology 234:2299–2309. 10.1007/s00213-017-4648-z
24. D’Souza DC, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T, Planeta B, Neumeister A, Pittman B, Normandin MD, Kapinos M, Ropchan J, Huang Y, Carson RE, Skosnik PD (2016) Rapid changes in cannabinoid 1 receptor availability in cannabis-dependent male subjects after abstinence from cannabis. Biol Psychiatry Cogn Neurosci Neuroimaging 1:60–67. 10.1016/j.bpsc.2015.09.008
25. Danovitch I, Gorelick DA (2012) State of the art treatments for cannabis dependence. Psychiatr Clin North Am 35:309–326. 10.1016/j.psc.2012.03.003
26. Davis JP, Smith DC, Morphew JW, Lei X, Zhang S (2016) Cannabis withdrawal, posttreatment abstinence, and days to first cannabis use among emerging adults in substance use treatment. J Drug Issues 46:64–83. 10.1177/0022042615616431
27. Dorard G, Berthoz S, Phan O, Corcos M, Bungener C (2008) Affect dysregulation in cannabis abusers: a study in adolescents and young adults. Eur Child Adolesc Psychiatry 17:274–282. 10.1007/s00787-007-0663-7
28. Dow-Edwards D, Silva L (2017) Endocannabinoids in brain plasticity: cortical maturation, HPA axis function and behavior. Brain Res 1654:157–164. 10.1016/j.brainres.2016.08.037
29. Draycott B, Loureiro M, Ahmad T, Tan H, Zunder J, Laviolette SR (2014) Cannabinoid transmission in the prefrontal cortex bi-phasically controls emotional memory formation via functional interactions with the ventral tegmental area. J Neurosci 34:13096–13109. 10.1523/JNEUROSCI.1297-14.2014
30. ElSohly MA, Mehmedic Z, Foster S et al (2016) Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiatry 79:613–619. 10.1016/j.biopsych.2016.01.004
31. Filbey FM, Dunlop J, Myers US (2013) Neural effects of positive and negative incentives during marijuana withdrawal. PLoS One 8:e61470. 10.1371/journal.pone.0061470
32. Filbey FM, Dunlop J, Ketcherside A, Baine J, Rhinehardt T, Kuhn B, DeWitt S, Alvi T (2016) fMRI study of neural sensitization to hedonic stimuli in long-term, daily cannabis users. Hum Brain Mapp 37:3431–3443. 10.1002/hbm.23250
33. Food and Drug Administration (2007) FDA briefing document. NDA 21-888. Zimulti (rimonabant) tablets, 20 mg. Sanofi Aventis. Advisory Committee–June 13, 2007
34. Gates P, Albertella L, Copeland J (2016) Cannabis withdrawal and sleep: a systematic review of human studies. Subst Abus 37:255–269. 10.1080/08897077.2015.1023484
35. Gilman JM, Kuster JK, Lee S, Lee MJ, Kim BW, Makris N, van der Kouwe A, Blood AJ, Breiter HC (2014) Cannabis use is quantitatively associated with nucleus accumbens and amygdala abnormalities in young adult recreational users. J Neurosci 34:5529–5538. 10.1523/JNEUROSCI.4745-13.2014
36. Goyal H, Awad HH, Ghali JK (2017) Role of cannabis in cardiovascular disorders. J Thorac Dis 9:2079–2092. 10.21037/jtd.2017.06.104
37. Hasin DS (2018) US epidemiology of cannabis use and associated problems. Neuropsychopharmacology 43:195–212. 10.1038/npp.2017.198
38. Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, Jung J, Pickering RP, Ruan WJ, Smith SM, Huang B, Grant BF (2015) Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiat 72:1235–1242. 10.1001/jamapsychiatry.2015.1858
39. Heitzeg MM, Cope LM, Martz ME, Hardee JE, Zucker RA (2015) Brain activation to negative stimuli mediates a relationship between adolescent marijuana use and later emotional functioning. Dev Cogn Neurosci 16:71–83. 10.1016/j.dcn.2015.09.003
40. Henry KL, Augustyn MB (2017) Intergenerational continuity in cannabis use: the role of parent’s early onset and lifetime disorder on child’s early onset. J Adolesc Health 60:87–92. 10.1016/j.jadohealth.2016.09.005
41. Hirvonen J, Goodwin RS, Li C-T, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow ND, Huestis MA, Innis RB (2012) Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry 17:642–649. 10.1038/mp.2011.82
42. Jackson NJ, Isen JD, Khoddam R, Irons D, Tuvblad C, Iacono WG, McGue M, Raine A, Baker LA (2016) Impact of adolescent marijuana use on intelligence: results from two longitudinal twin studies. Proc Natl Acad Sci U S A 113:E500–E508. 10.1073/pnas.1516648113
43. Jasinska AJ, Stein EA, Kaiser J, Naumer MJ, Yalachkov Y (2014) Factors modulating neural reactivity to drug cues in addiction: a survey of human neuroimaging studies. Neurosci Biobehav Rev 38:1–16. 10.1016/j.neubiorev.2013.10.013
44. Karila L, Roux P, Rolland B, Benyamina A, Reynaud M, Aubin HJ, Lancon C (2014) Acute and long-term effects of cannabis use: a review. Curr Pharm Des 20:4112–4118. 10.2174/13816128113199990620
45. Katsidoni V, Kastellakis A, Panagis G (2013) Biphasic effects of Δ9-tetrahydrocannabinol on brain stimulation reward and motor activity. Int J Neuropsychopharmacol 16:2273–2284. 10.1017/S1461145713000709
46. Katz G, Lobel T, Tetelbaum A, Raskin S (2014) Cannabis withdrawal - a new diagnostic category in DSM-5. Isr J Psychiatry Relat Sci 51:270–275
47. Koenders L, Cousijn J, Vingerhoets WAM, van den Brink W, Wiers RW, Meijer CJ, Machielsen MWJ, Veltman DJ, Goudriaan AE, de Haan L (2016) Grey matter changes associated with heavy cannabis use: a longitudinal sMRI study. PLoS One 11:e0152482. 10.1371/journal.pone.0152482
48. Kolb B, Li Y, Robinson T, Parker LA (2018) THC alters alters morphology of neurons in medial prefrontal cortex, orbital prefrontal cortex, and nucleus accumbens and alters the ability of later experience to promote structural plasticity. Synapse 72. 10.1002/syn.22020
49. Koob GF, Mason BJ (2016) Existing and future drugs for the treatment of the dark side of addiction. Annu Rev Pharmacol Toxicol 56:299–322. 10.1146/annurev-pharmtox-010715-103143
50. Koob GF, Volkow ND (2016) Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 3:760–773. 10.1016/S2215-0366(16)00104-8
51. Lefever TW, Marusich JA, Antonazzo KR, Wiley JL (2014) Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model. Pharmacol Biochem Behav 118:30–35. 10.1016/j.pbb.2014.01.002
52. Levin FR, Mariani JJ, Pavlicova M, Brooks D, Glass A, Mahony A, Nunes EV, Bisaga A, Dakwar E, Carpenter KM, Sullivan MA, Choi JC (2016) Dronabinol and lofexidine for cannabis use disorder: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 159:53–60. 10.1016/j.drugalcdep.2015.11.025
53. Lorenzetti V, Solowij N, Whittle S, Fornito A, Lubman DI, Pantelis C, Yücel M (2015) Gross morphological brain changes with chronic, heavy cannabis use. Br J Psychiatry 206:77–78. 10.1192/bjp.bp.114.151407
54. Maldonado R, Rodriguez de Fonseca F (2002) Cannabinoid addiction: behavioral models and neural correlates. J Neurosci 22:3326–3331. 20026358
55. Maldonado R, Berrendero F, Ozaita A, Robledo P (2011) Neurochemical basis of cannabis addiction. Neuroscience 181:1–17. 10.1016/j.neuroscience.2011.02.035
56. Manza P, Tomasi D, Volkow ND (2018) Subcortical local functional hyperconnectivity in cannabis dependence. Biol Psychiatry Cogn Neurosci Neuroimaging 3:285–293. 10.1016/j.bpsc.2017.11.004
57. Martinez D, Saccone PA, Liu F, Slifstein M, Orlowska D, Grassetti A, Cook S, Broft A, van Heertum R, Comer SD (2012) Deficits in dopamine D 2 receptors and presynaptic dopamine in heroin dependence: commonalities and differences with other types of addiction. Biol Psychiatry 71:192–198. 10.1016/j.biopsych.2011.08.024
58. Martz ME, Trucco EM, Cope LM, Hardee JE, Jester JM, Zucker RA, Heitzeg MM (2016) Association of marijuana use with blunted nucleus accumbens response to reward anticipation. JAMA Psychiat 73:838–844. 10.1001/jamapsychiatry.2016.1161
59. Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, Buffkins K, Kyle M, Adusumalli M, Begovic A, Rao S (2012) A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 37:1689–1698. 10.1038/npp.2012.14
60. Meier MH, Caspi A, Danese A, Fisher HL, Houts R, Arseneault L, Moffitt TE (2018) Associations between adolescent cannabis use and neuropsychological decline: a longitudinal co-twin control study. Addiction 113:257–265. 10.1111/add.13946
61. Melis M, Frau R, Kalivas PW, Spencer S, Chioma V, Zamberletti E, Rubino T, Parolaro D (2017) New vistas on cannabis use disorder. Neuropharmacology 124:62–72. 10.1016/j.neuropharm.2017.03.033
62. Moreno-Lopez L, Stamatakis EA, Fernandez-Serrano MJ et al (2012) Neural correlates of the severity of cocaine, heroin, alcohol, MDMA and cannabis use in polysubstance abusers: a resting-PET brain metabolism study. PLoS One 7:e39830. 10.1371/journal.pone.0039830
63. Morgan CJ, Freeman TP, Schafer GL, Curran HV (2010) Cannabidiol attenuates the appetitive effects of Δ9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 35:1879–1885. 10.1038/npp.2010.58
64. Ng Cheong Ton JM, Gerhardt GA, Friedemann M, Etgen AM, Rose GM, Sharpless NS, Gardner EL (1988) The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study. Brain Res 451:59–68
65. Norberg MM, Kavanagh DJ, Olivier J, Lyras S (2016) Craving cannabis: a meta-analysis of self-report and psychophysiological cue-reactivity studies. Addiction 111:1923–1934. 10.1111/add.13472
66. Oleson EB, Cheer JF (2012) A brain on cannabinoids: the role of dopamine release in reward seeking. Cold Spring Harb Perspect Med 2:1–14. 10.1101/cshperspect.a012229
67. Pacher P, Steffens S, Haskó G, Schindler TH, Kunos G (2017) Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol 15:151–166. 10.1038/nrcardio.2017.130
68. Panlilio L, Goldberg S, Justinova Z (2015) Cannabinoid abuse and addiction: clinical and preclinical findings. Clin Pharmacol Ther 97:616–627. 10.1002/cpt.118
69. Parsons LH, Hurd YL (2015) Endocannabinoid signalling in reward and addiction. Nat Rev Neurosci 16:579–594. 10.1038/nrn4004
70. Paule MG, Allen RR, Bailey JR, Scallet AC, Ali SF, Brown RM, Slikker W Jr (1992) Chronic marijuana smoke exposure in the rhesus monkey. II: effects on progressive ratio and conditioned position responding. J Pharmacol Exp Ther 260:210–222
71. Pujol J, Blanco-Hinojo L, Batalla A, López-Solà M, Harrison BJ, Soriano-Mas C, Crippa JA, Fagundo AB, Deus J, de la Torre R, Nogué S, Farré M, Torrens M, Martín-Santos R (2014) Functional connectivity alterations in brain networks relevant to self-awareness in chronic cannabis users. J Psychiatr Res 51:68–78. 10.1016/j.jpsychires.2013.12.008
72. Renard J, Vitalis T, Rame M, Krebs MO, Lenkei Z, le Pen G, Jay TM (2016) Chronic cannabinoid exposure during adolescence leads to long-term structural and functional changes in the prefrontal cortex. Eur Neuropsychopharmacol 26:55–64. 10.1016/j.euroneuro.2015.11.005
73. Rodriguez de Fonseca F, Carrera MR, Navarro M et al (1997) Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276:2050–2054
74. Samuni Y, Goldstein S, Dean OM, Berk M (2013) The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta Gen Subj 1830:4117–4129. 10.1016/j.bbagen.2013.04.016
75. Scherma M, Dessi C, Muntoni AL et al (2016) Adolescent Delta(9)-Tetrahydrocannabinol exposure alters WIN55,212-2 self-administration in adult rats. Neuropsychopharmacology 41:1416–1426. 10.1038/npp.2015.295
76. Seip-Cammack KM, Reed B, Zhang Y, Ho A, Kreek MJ (2013) Tolerance and sensitization to chronic escalating dose heroin following extended withdrawal in fischer rats: possible role of mu-opioid receptors. Psychopharmacology 225:127–140. 10.1007/s00213-012-2801-2
77. Sevy S, Smith GS, Ma Y, Dhawan V, Chaly T, Kingsley PB, Kumra S, Abdelmessih S, Eidelberg D (2008) Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography. Psychopharmacology 197:549–556. 10.1007/s00213-008-1075-1
78. Somaini L, Manfredini M, Amore M, Zaimovic A, Raggi MA, Leonardi C, Gerra ML, Donnini C, Gerra G (2012) Psychobiological responses to unpleasant emotions in cannabis users. Eur Arch Psychiatry Clin Neurosci 262:47–57. 10.1007/s00406-011-0223-5
79. Spechler PA, Orr CA, Chaarani B, Kan KJ, Mackey S, Morton A, Snowe MP, Hudson KE, Althoff RR, Higgins ST, Cattrell A, Flor H, Nees F, Banaschewski T, Bokde ALW, Whelan R, Büchel C, Bromberg U, Conrod P, Frouin V, Papadopoulos D, Gallinat J, Heinz A, Walter H, Ittermann B, Gowland P, Paus T, Poustka L, Martinot JL, Artiges E, Smolka MN, Schumann G, Garavan H, IMAGEN Consortium (2015) Cannabis use in early adolescence: evidence of amygdala hypersensitivity to signals of threat. Dev Cogn Neurosci 16:63–70. 10.1016/j.dcn.2015.08.007
80. Stephens MAC, Wand G (2012) Stress and the HPA axis: role of glucocorticoids in alcohol dependence. Alcohol Res 34:468–483
81. Stokes PRA, Egerton A, Watson B, Reid A, Breen G, Lingford-Hughes A, Nutt DJ, Mehta MA (2010) Significant decreases in frontal and temporal [11C]-raclopride binding after THC challenge. NeuroImage 52:1521–1527. 10.1016/j.neuroimage.2010.04.274
82. Suarez-Pinilla P, Lopez-Gil J, Crespo-Facorro B (2014) Immune system: a possible nexus between cannabinoids and psychosis. Brain Behav Immun 40:269–282. 10.1016/j.bbi.2014.01.018
83. Tanda G, Goldberg SR (2003) Cannabinoids: reward, dependence, and underlying neurochemical mechanisms - a review of recent preclinical data. Psychopharmacology 169:115–134. 10.1007/s00213-003-1485-z
84. Taylor D (2009) Withdrawal of Rimonabant--walking the tightrope of 21st century pharmaceutical regulation? Curr Drug Saf 4:2–4
85. Thomas G, Kloner RA, Rezkalla S (2018) Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. Am J Cardiol 113:187–190. 10.1016/j.amjcard.2013.09.042
86. Tomasi D, Wang G-J, Wang R, Caparelli EC, Logan J, Volkow ND (2015a) Overlapping patterns of brain activation to food and cocaine cues in cocaine abusers: association to striatal D2/D3 receptors. Hum Brain Mapp 36:120–136. 10.1002/hbm.22617
87. Tomasi D, Wang GJ, Volkow ND (2015b) Balanced modulation of striatal activation from D2/D3receptors in caudate and ventral striatum: disruption in cannabis abusers. Hum Brain Mapp 36:3154–3166. 10.1002/hbm.22834
88. Tsang CC, Giudice MG (2016) Nabilone for the management of pain. Pharmacotherapy 36:273–286. 10.1002/phar.1709
89. Urban NBL, Slifstein M, Thompson JL, Xu X, Girgis RR, Raheja S, Haney M, Abi-Dargham A (2012) Dopamine release in chronic cannabis users: a [11C]raclopride positron emission tomography study. Biol Psychiatry 71:677–683. 10.1016/j.biopsych.2011.12.018
90. van de Giessen E, Weinstein JJ, Cassidy CM, Haney M, Dong Z, Ghazzaoui R, Ojeil N, Kegeles LS, Xu X, Vadhan NP, Volkow ND, Slifstein M, Abi-Dargham A (2017) Deficits in striatal dopamine release in cannabis dependence. Mol Psychiatry 22:68–75. 10.1038/mp.2016.21
91. Vandrey R, Haney M (2009) Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs 23:543–553. 10.2165/00023210-200923070-00001
92. Volkow ND, Gillespie H, Mullani N, Tancredi L, Grant C, Valentine A, Hollister L (1996a) Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication. Psychiatry Res 67:29–38
93. Volkow ND, Wang GJ, Fowler JS, Logan J, Hitzemann R, Ding YS, Pappas N, Shea C, Piscani K (1996b) Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin Exp Res 20:1594–1598
94. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Wong C, Hitzemann R, Pappas NR (1999a) Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. J Pharmacol Exp Ther 291:409–415
95. Volkow ND, Wang GJ, Fowler JS, Hitzemann R, Angrist B, Gatley SJ, Logan J, Ding YS, Pappas N (1999b) Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. Am J Psychiatry 156:19–26. 10.1176/ajp.156.1.19
96. Volkow ND, Chang L, Wang GJ, Fowler JS, Ding YS, Sedler M, Logan J, Franceschi D, Gatley J, Hitzemann R, Gifford A, Wong C, Pappas N (2001) Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 158:2015–2021. 10.1176/appi.ajp.158.12.2015
97. Volkow ND, Wang G-J, Maynard L, Fowler JS, Jayne B, Telang F, Logan J, Ding YS, Gatley SJ, Hitzemann R, Wong C, Pappas N (2002) Effects of alcohol detoxification on dopamine D2 receptors in alcoholics: a preliminary study. Psychiatry Res 116:163–172
98. Volkow ND, Wang G-J, Ma Y, Fowler JS, Wong C, Ding YS, Hitzemann R, Swanson JM, Kalivas P (2005) Activation of orbital and medial prefrontal cortex by methylphenidate in cocaine-addicted subjects but not in controls: relevance to addiction. J Neurosci 25:3932–3939. 10.1523/JNEUROSCI.0433-05.2005
99. Volkow ND, Baler RD, Compton WM, Weiss SRB (2014a) Adverse health effects of marijuana use. N Engl J Med 370:2219–2227. 10.1056/NEJMra1402309
100. Volkow ND, Tomasi D, Wang G-J, Logan J, Alexoff DL, Jayne M, Fowler JS, Wong C, Yin P, du C (2014b) Stimulant-induced dopamine increases are markedly blunted in active cocaine abusers. Mol Psychiatry 19:1037–1043. 10.1038/mp.2014.58
101. Volkow ND, Wang G-J, Telang F, Fowler JS, Alexoff D, Logan J, Jayne M, Wong C, Tomasi D (2014c) Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. Proc Natl Acad Sci 111:E3149–E3156. 10.1073/pnas.1411228111
102. Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, Bloomfield MAP, Curran HV, Baler R (2016) Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiat 73:292–297. 10.1001/jamapsychiatry.2015.3278
103. Volkow ND, Hampson AJ, Baler RD (2017a) Don’t worry, be happy: endocannabinoids and cannabis at the intersection of stress and reward. Annu Rev Pharmacol Toxicol 57:285–308. 10.1146/annurev-pharmtox-010716-104615
104. Volkow ND, Koob GF, Croyle RT, Bianchi DW, Gordon JA, Koroshetz WJ, Pérez-Stable EJ, Riley WT, Bloch MH, Conway K, Deeds BG, Dowling GJ, Grant S, Howlett KD, Matochik JA, Morgan GD, Murray MM, Noronha A, Spong CY, Wargo EM, Warren KR, Weiss SRB (2017b) The conception of the ABCD study: from substance use to a broad NIH collaboration. Dev Cogn Neurosci. 10.1016/j.dcn.2017.10.002
105. Volkow ND, Wiers CE, Shokri-Kojori E, Tomasi D, Wang GJ, Baler R (2017c) Neurochemical and metabolic effects of acute and chronic alcohol in the human brain: studies with positron emission tomography. Neuropharmacology 122:175–188. 10.1016/j.neuropharm.2017.01.012
106. Wang GJ, Volkow ND, Fowler JS, Logan J, Abumrad NN, Hitzemann RJ, Pappas NS, Pascani K (1997) Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology 16:174–182. 10.1016/S0893-133X(96)00184-4
107. Wang GJ, Smith L, Volkow ND, Telang F, Logan J, Tomasi D, Wong CT, Hoffman W, Jayne M, Alia-Klein N, Thanos P, Fowler JS (2012) Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry 17:918–925. 10.1038/mp.2011.86
108. Weiland BJ, Thayer RE, Depue BE, Sabbineni A, Bryan AD, Hutchison KE (2015) Daily marijuana use is not associated with brain morphometric measures in adolescents or adults. J Neurosci 35:1505–1512. 10.1523/JNEUROSCI.2946-14.2015
109. Wiers CE, Cabrera E, Skarda E et al (2016a) PET imaging for addiction medicine: from neural mechanisms to clinical considerations. Prog Brain Res 224:175–201. 10.1016/bs.pbr.2015.07.016
110. Wiers CE, Shokri-Kojori E, Wong CT, Abi-Dargham A, Demiral ŞB, Tomasi D, Wang GJ, Volkow ND (2016b) Cannabis abusers show hypofrontality and blunted brain responses to a stimulant challenge in females but not in males. Neuropsychopharmacology 41:2596–2605. 10.1038/npp.2016.67
111. Wiers CE, Cabrera EA, Tomasi D, Wong CT, Demiral ŞB, Kim SW, Wang GJ, Volkow ND (2017) Striatal dopamine D2/D3 receptor availability varies across smoking status. Neuropsychopharmacology 42:2325–2332. 10.1038/npp.2017.131
112. Wijayendran SB, O’Neill A, Bhattacharyya S (2016) The effects of cannabis use on salience attribution: a systematic review. Acta Neuropsychiatr 30:1–15. 10.1017/neu.2016.58
113. Wilson SJ, Sayette MA (2015) Neuroimaging craving: urge intensity matters. Addiction 110:195–203. 10.1111/add.12676
114. Yip SW, DeVito EE, Kober H et al (2014) Pretreatment measures of brain structure and reward-processing brain function in cannabis dependence: an exploratory study of relationships with abstinence during behavioral treatment1. Drug Alcohol Depend 140:33–41. 10.1016/j.drugalcdep.2014.03.031
115. Zanda MT, Fattore L (2018) Old and new synthetic cannabinoids: lessons from animal models. Drug Metab Rev 50:1–11. 10.1080/03602532.2018.1430824
116. Zimmermann K, Yao S, Heinz M, Zhou F, Dau W, Banger M, Weber B, Hurlemann R, Becker B (2018) Altered orbitofrontal activity and dorsal striatal connectivity during emotion processing in dependent marijuana users after 28 days of abstinence. Psychopharmacology 235:849–859. 10.1007/s00213-017-4803-6